

**ELI WHITNEY INVESTMENT COMMITTEE**  
of Connecticut Innovations, Incorporated  
Minutes – Special Meeting  
Wednesday, February 10, 2021

A special meeting of the **Eli Whitney Investment Committee of Connecticut Innovations, Incorporated** (the “Investment Committee”) was held electronically through Microsoft Teams on February 10, 2021.

**1. Call to Order:**

Rafael Santiago, Chairperson, of the Investment Committee, noting the presence of a quorum, called the Eli Whitney Investment Committee meeting to order at 3:00 p.m. Other Investment Committee members present: Radenka Maric, Ph.D.; and Richard Mulready.

Absent: John Pavia and Andre Swanston.

CI Board Members Attending: Michael Cantor, Chairperson of the CI Board

Staff attending: Peter Longo; Heidi Marshall; Matthew McCooe; Pauline Murphy; and David Wurzer.

**2. Portfolio Company Opportunities:**

**“Tantalus Systems Holdings, Inc. – Norwalk, CT and Vancouver, BC”**

Mr. Wurzer reviewed with the Committee a proposed merger of Tantalus Systems Holding, Inc. into RiseTech Capital Corp.

A discussion ensued.

**Upon a motion made by Mr. Mulready, and seconded by Dr. Maric, the Investment Committee unanimously approved CI’s exchange of its holdings in Tantalus Systems Holding, Inc. for shares of RiseTech Capital Corp., to be subsequently renamed Tantalus Systems, Inc., under the terms as proposed.**

**RESOLVED:**

**(1) that the transaction is approved by Connecticut Innovations, Inc. (“CI”) for CI’s exchange of its holdings in Tantalus Systems Holding, Inc. for shares of RiseTech Capital Corp., to be subsequently renamed Tantalus Systems, Inc., under the terms as proposed; and**

(2) that Matthew McCooe, Chief Executive Officer; David Wurzer, Executive Vice President & Chief Investment Officer; Philip Siuta, Senior Vice President, Chief Financial Officer & Chief Operating Officer; or Peter Longo, Senior Managing Director, Investments, each an “Authorized Signatory”, are authorized to execute and deliver for and on behalf of CI such agreements and related documents to cause such investment to be effected, which documents shall (a) be executed by CI no later than August 10, 2021; and (b) contain such terms and conditions as the Authorized Signatory shall deem to be in the best interests of CI, including terms and conditions relating to the matters described in Section 6 of the Regulations, the Authorized Signatory’s approval thereof as hereby authorized to be conclusively evidenced by the execution and delivery of the agreements; and

(3) that the Authorized Signatories hereby are severally authorized and empowered to do any and all acts and execute and deliver any and all other documents as they shall deem necessary and desirable to effectuate the above-mentioned agreements.

**“Mount Sinai Genomics, Inc. (d/b/a Sema4) – Stamford, CT”**

Mr. Wurzer reviewed with the Committee a proposed merger of Sema4 into CM Life Sciences, Inc.

A discussion ensued.

Upon a motion made by Mr. Mulready, and seconded by Dr. Maric, the Investment Committee unanimously approved CI’s exchange of its holdings in Sema4 for shares of CM Life Sciences, Inc., under the terms as proposed.

**RESOLVED:**

(1) that the transaction is approved by Connecticut Innovations, Inc. (“CI”) for CI’s exchange of its holdings in Mount Sinai Genomics, Inc. (d/b/a Sema4) for shares of CM Life Sciences, Inc., under the terms as proposed; and

(2) that Matthew McCooe, Chief Executive Officer; David Wurzer, Executive Vice President & Chief Investment Officer; Philip Siuta, Senior Vice President, Chief Financial Officer & Chief Operating Officer; or Peter Longo, Senior Managing Director, Investments, each an “Authorized Signatory”, are authorized to execute and deliver for and on behalf of CI such agreements and related documents to cause such investment to be effected, which documents shall (a) be executed by CI no later than August 10, 2021; and (b) contain such terms and conditions as the Authorized Signatory shall deem to be in the best interests of CI, including terms and conditions relating to the matters described in Section 6 of the Regulations, the Authorized Signatory’s approval thereof as hereby

authorized to be conclusively evidenced by the execution and delivery of the agreements; and

(3) that the Authorized Signatories hereby are severally authorized and empowered to do any and all acts and execute and deliver any and all other documents as they shall deem necessary and desirable to effectuate the above-mentioned agreements.

3. **Date for Next Meeting:**

March 4, 2021 at 10:30 a.m.

4. **Adjournment:**

Upon a motion made by Mr. Mulready, and seconded by Dr. Maric, the Investment Committee members voted unanimously in favor of adjourning the February 10, 2021 special meeting at 3:11 p.m.

Respectfully submitted,



[Rafael Santiago \(Mar 6, 2021 09:15 AST\)](#)

---

Rafael Santiago  
Chairperson of the Eli Whitney  
Investment Committee






# 021021 ElilnvMlnutes Final

Final Audit Report

2021-03-06

Created:	2021-03-05
By:	Heidi Marshall (heidi.marshall@ctinnovations.com)
Status:	Signed
Transaction ID:	CBJCHBCAABAA9HdgbOeQgvgQx3dpvTwsE9IR6R6NVVeo

## "021021 ElilnvMlnutes Final" History

-  Document created by Heidi Marshall (heidi.marshall@ctinnovations.com)  
2021-03-05 - 3:37:50 PM GMT- IP address: 68.226.92.173
-  Document emailed to Rafael Santiago (rsantiago@santiagolawgroup.com) for signature  
2021-03-05 - 3:38:19 PM GMT
-  Email viewed by Rafael Santiago (rsantiago@santiagolawgroup.com)  
2021-03-05 - 3:43:15 PM GMT- IP address: 24.50.226.194
-  Document e-signed by Rafael Santiago (rsantiago@santiagolawgroup.com)  
Signature Date: 2021-03-06 - 1:15:52 PM GMT - Time Source: server- IP address: 24.50.226.194
-  Agreement completed.  
2021-03-06 - 1:15:52 PM GMT